Cancer incidence results* for employees of a Canadian petroleum company, by gender, 1969–94
| Type of malignancy (ICD codes, 9th revision) | Males | Females | ||
|---|---|---|---|---|
| O/E | SIR (95% CI) | O/E | SIR (95% CI) | |
| *Expected malignancies based on Canadian general population cancer incidence rates. | ||||
| †95* CI does not include 1.00. | ||||
| O/E, observed/expected. | ||||
| Total malignant neoplasms (140–208) | 325/379.11† | 0.86 (0.77 to 0.96) | 184/212.16† | 0.87 (0.75 to 1.00) |
| Oesophagus (150) | 3/4.33 | – | 0/0.48 | – |
| Stomach (151) | 6/12.09 | 0.50 (0.18 to 1.08) | 0/2.59 | – |
| Large intestine (except rectum) (153, 159.0) | 33/27.84 | 1.18 (0.82 to 1.66) | 12/10.72 | 1.12 (0.58 to 1.96) |
| Rectum and rectosigmoid junction (154) | 15/18.74 | 0.80 (0.45 to 1.32) | 4/5.31 | 0.75 (0.20 to 1.93) |
| Liver (155.0) | 2/3.14 | – | 0/0.46 | – |
| Gall bladder (156) | 5/1.76 | 2.84 (0.92 to 6.62) | 0/0.87 | – |
| Pancreas (157) | 5/8.42 | 0.59 (0.19 to 1.39) | 0/2.27 | – |
| Nose & sinuses (160) | 2/1.19 | – | 1/0.31 | – |
| Bronchus & lung (162.2–162.5, 162.8–162.9) | 44/63.98† | 0.69 (0.50 to 0.92) | 9/15.29 | 0.59 (0.27 to 1.12) |
| Pleura (163) | 3/1.27 | – | 0/0.14 | – |
| Bone (170) | 4/2.30 | – | 0/0.81 | – |
| Malignant melanoma (172) | 26/20.84 | 1.25 (0.82 to 1.83) | 16/10.97 | 1.46 (0.83 to 2.37) |
| Breast (174–175) | 0/0.73 | – | 76/74.45 | 1.02 (0.80 to 1.28) |
| Cervix uteri (180) | 7/16.81† | 0.42 (0.17 to 0.86) | ||
| Corpus uteri (182) | 3/9.81† | 0.31 (0.06 to 0.89) | ||
| Ovary, fallopian tube, & broad ligaments (183) | 15/10.75 | 1.40 (0.78 to 2.30) | ||
| Prostate (185) | 20/30.05 | 0.67 (0.41 to 1.03) | ||
| Testis (186) | 14/17.10 | 0.82 (0.45 to 1.37) | ||
| Bladder (188) | 18/19.52 | 0.92 (0.55 to 1.46) | 2/2.75 | – |
| Kidney (189.0–189.2) | 15/15.01 | 1.00 (0.56 to 1.65) | 2/3.49 | – |
| Brain (malignant) (191) | 16/14.04 | 1.14 (0.65 to 1.85) | 5/4.14 | 1.21 (0.40 to 2.82) |
| Malignant CNS (excluding brain) (192.0–192.9) | 0/1.08 | – | 1/0.45 | – |
| Reticulum cell sarcoma (200.0) | 6/4.86 | 1.24 (0.45 to 2.69) | 1/1.41 | – |
| Lymphosarcoma (200.1) | 4/3.52 | – | 2/1.00 | – |
| Hodgkin’s disease (201) | 11/10.46 | 1.05 (0.52 to 1.88) | 3/3.34 | – |
| Non-Hodgkin’s lymphoma (200.0–200.2, 202.0, 202.8) | 20/20.57 | 0.97 (0.59 to 1.50) | 7/5.87 | 1.19 (0.48 to 2.46) |
| Other lymphoid neoplasms (200.8, 202.1, 202.9) | 4/3.61 | – | 0/0.96 | – |
| Multiple myeloma (203.0) | 3/3.66 | – | 0/1.09 | – |
| Leukaemias (204–206, 207.0, 207.2, 207.8, 208) | 13/13.49 | 0.96 (0.51 to 1.65) | 3/4.23 | – |
| Acute non-lymphocytic leukaemia (205.0, 206.0, 207.0) | 4/4.13 | – | 2/1.66 | – |
| Acute lymphoid leukaemia (204.0) | 2/1.42 | – | 0/0.42 | – |
| Chronic lymphoid leukaemia (204.1) | 6/3.32 | 1.81 (0.66 to 3.94) | 0/0.66 | – |
| Acute myeloid (myelomonocytic) leukaemia (205.0) | 3/3.79 | – | 2/1.54 | – |
| Chronic myeloid leukaemia (205.1) | 0/2.84 | – | 1/0.86 | – |
| Other leukaemias (204.2–204.9, 205.2–205.9, 206.1–206.9, 207.2–207.8, 208.0–208.9) | 1/1.67 | – | 0/0.59 | – |